Anjarium Biosciences’ CHF 55.5 Million Series A Financing Round

VISCHER advised Anjarium Biosciences on the deal. Baker McKenzie advises a consortium of life science funds, including Abingworth and Gimv, alongside Omega Funds, Pfizer Ventures and Surveyor Capital.

Anjarium Biosciences AG, a biotech company in Schlieren (ZH) focused on creating and delivering a new class of non-viral gene therapies has closed a CHF55.5m (USD 61m) Series A Financing.

The round was co-led by Abingworth and Gimv, with significant participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).

Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic disease throughout a patient’s lifetime. The Company’s versatile platform – including its novel HybridosomeTM technology – aims to leverage breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies.

The Vischer team included Matthias Staehelin (Picture) and Pauline Pfirter (both Coporate/M&A).

The Baker McKenzie team was led by Partner Martin Frey (Picture) and Associate Kevin Ardüser.

Involved fees earner: Kevin Ardüser – Baker McKenzie; Martin Frey – Baker McKenzie; Pauline Pfirter – VISCHER AG; Matthias Staehelin – VISCHER AG;

Law Firms: Baker McKenzie; VISCHER AG;

Clients: Pfizer Ventures; Abingworth; Anjarium Biosciences AG; Gimv NV; Omega Funds; Surveyor Capital;

Author: Federica Tiefenthaler